Matthew Goldberg

About Matthew Goldberg

Traditional histopathology remains the foundation of diagnostic medicine. It is highly effective for identifying disease and guiding initial treatment decisions. Yet one of the most pressing gaps in laboratory medicine is its limited ability to provide prognostic insight. In many disease states, histopathology alone is limited to both stratify risk and guide personalized treatment decisions. 

At Castle Biosciences, my work centers on addressing this gap by developing, validating, and integrating advanced laboratory-developed molecular diagnostic tests. Our goal is to complement and extend traditional pathology using the same biopsy samples already collected. These tests are not generic panels – they are purpose-built to meet specific, unmet clinical needs through technologies such as gene expression profiling, sequencing, and spatial biology. By enhancing the accuracy and relevance of prognostic information, we help clinicians make more risk-aligned treatment decisions.

A major challenge in adopting molecular diagnostics is clinician education. Many physicians and pathologists were never exposed to these tools during their training and may be uncertain about when and how to use them. To close this gap, I focus on building and sharing strong clinical evidence, engaging in outreach across pathology, dermatology, and oncology communities, and supporting integration into practice. This includes active participation in policy and reimbursement discussions, such as Local Coverage Determination (LCD) processes with Medicare Administrative Contractors, to expand patient access.

Innovation is about more than creating new tests – it is about redefining the laboratory’s role in modern medicine. By pinpointing where histopathology falls short prognostically, and where molecular diagnostics add clarity, we are helping reshape care pathways to be more precise, evidence-driven, and patient-centered.

Our commitment – rooted in science, guided by clinical need, and supported by education and policy engagement – is how we are addressing critical gaps in laboratory medicine and shaping the future of personalized care.